17 results
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
Measures:
Tolerability assessment: Adverse event monitoring, patient-reported outcomes.
Efficacy assessment: Depression rating scales (e.g., HDRS … of use.
Figure: Summary of assessment by IQVIA of valuation of Ketamir-2, including the background, commercial opportunity, and drivers of valuation
424B4
MIRA
Mira Pharmaceuticals Inc
4 Aug 23
Prospectus supplement with pricing info
1:01pm
potentially improve cognitive assessment outcomes by reducing anxiety levels that may otherwise hinder cognitive functioning.
Therefore, in commonly … the impairment assessment process. Acquisitions may also result in dilutive issuances of equity securities or the incurrence of debt, which could adversely
424B1
MIRA
Mira Pharmaceuticals Inc
4 Aug 23
Prospectus with pricing info
12:59pm
was complicated by the following:
MIRA1a has anti-anxiety (i.e. anxiolytic) effects, and
anxiolytics can potentially improve cognitive assessment outcomes … acquisitions do not yield expected returns, we may be required to take charges to our operating results arising from the impairment assessment process
S-1
EX-99.3
ljlbg4
29 Jun 23
IPO registration
4:39pm
S-1
EX-99.2
d948jat7 b5q
29 Jun 23
IPO registration
4:39pm
S-1
EX-99.1
jx706
29 Jun 23
IPO registration
4:39pm
S-1
dlcj2 i4zuvy4
29 Jun 23
IPO registration
4:39pm
DRS/A
EX-99.2
0qf0pq
8 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
EX-99.3
x093mp8d4vd9or9ywyw0
8 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
jw0buyu9rivgsgu
8 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
EX-99.1
xm4sp
8 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
oiwj0
2 May 23
Draft registration statement (amended)
12:00am
DRS
g71pf
29 Jun 22
Draft registration statement
12:00am
- Prev
- 1
- Next